疫苗板块拉升走强 钟南山称全球通过疫苗免疫需二到三年
格隆汇5月14日丨疫苗板块拉升走强,西藏药业涨停,沃森生物大涨超8%,康希诺涨超5%,复星医药、未名医药、康泰生物等跟涨。

昨日,中国工程院院士钟南山表示,数据显示目前中国新冠疫苗接种率在23%左右,这远远不够,至少需要达到70%-80%的接种率,这是一个艰巨的任务。
钟南山称,自然感染会造成70%-80%的感染率和5%的死亡率,因此“自然免疫不现实、不科学、不人道。”同时,实现群体免疫的另一种方式是大规模疫苗接种,这需要2-3年时间的全球协作。在疫苗有效性达到70%的时候,要实现群体免疫,全球、中国、亚洲以及欧洲接种率需分别达到89.2%、83.3%、80.2%、96.2%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.